ARCT — Arcturus Therapeutics Holdings

Is ARCT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Arcturus Therapeutics Holdings (ARCT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $8.31. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Arcturus Therapeutics is a small-cap RNA therapeutics company with a platform that could generate significant upside on positive clinical readouts or partnership/licensing deals. Near-term performance is constrained by limited visibility on cash runway and the unknowns flagged in a recent 8-K, while broader investor flows favor large-cap defensive healthcare rather than speculative biotech. Primary drivers over the coming weeks will be company disclosures, clinical milestones, and access to capital. Given the combination of meaningful upside potential tied to trial success and elevated execution and financing risk, a measured stance is warranted until clearer catalysts or financing clarity emerge.

Key factors

  • RNA therapeutic platform with diversified pipeline (mRNA/LNP delivery) that offers long-term upside if clinical programs advance
  • Strategic partnerships and technology licensing potential that can provide non-dilutive funding or validation
  • Cash runway and capital structure are uncertain; recent corporate filings (8-K) flagged in social feeds introduce near-term investor caution
  • Biotech sector environment is muted with rotation toward large-cap pharma and defensive names, reducing near-term speculative inflows
  • No major market-moving macro events in the short window, implying limited volatility but also limited catalysts in the immediate term
  • Clinical and regulatory milestones remain the primary potential catalysts for material re-rating

Risks

  • Clinical trial failures or slower-than-expected data readouts for lead programs
  • Regulatory setbacks or delays in approvals that would push out commercialization timelines
  • High cash burn with potential for dilution if capital markets access is constrained or equity needs to be raised
  • Competitive pressure from larger, better-funded RNA and biologics developers
  • Negative market reaction to company disclosures (e.g., the recent 8-K) increasing short-term volatility
  • Sector-wide rotation toward large-cap defensive pharma reducing investor appetite for small-cap biotech risk

See today's live rating, score and targets

Members see the live hourly rating for ARCT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.